ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-STEAP2/Exatecan Antibody-drug Conjugate AZD0516

Its studies are mostly in Prostatic Neoplasms, led by AstraZeneca.

Furthest: phase 2, since Sep 12, 20251 company-led study, 1 open or runningNext primary completion: Jan 18, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 2since Sep 12, 2025Sep 12, 2025Jan 18, 2029phase 2 · NCT07181161
  • Named in AstraZeneca’s own pipeline as AZD0516, phase 1, as of Oct 30, 2026 (source).

Also a collaborator on its studies: Parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT07181161 · 283 planned · United States, Brazil, China and more

Ahead

  1. Jan 18, 2029Primary completion: phase 2 study in Prostatic NeoplasmsNCT07181161

TargetBeta

“An antibody-drug conjugate (ADC) composed of a Fc-engineered monoclonal antibody targeting the tumor-associated antigen (TAA) six-transmembrane epithelial antigen of the prostate-2 (STEAP2; STEAP-2; STAMP1), linked via interchain cysteines to a maleimide-reactive, beta-glucuronidase-cleavable lin…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a Fc-engineered monoclonal antibody targeting the tumor-associated antigen (TAA) six-transmembrane epithelial antigen of the prostate-2 (STEAP2; STEAP-2; STAMP1), ”NCIt, by rule

Other programs on STEAP2

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07181161Prostatic Neoplasms · United States, Brazil, China and more2RecruitingJan 18, 2029283

How it is read

Names in the registry

  • “AZD0516”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.